Ocrelizumab (Ocrevus) is the newest infusion treatment for MS. It was approved by the FDA in 2017. It’s the first drug used to treat primary progressive MS (PPMS). It’s also used to treat CIS ...

It is also the first drug approved for patients with primary progressive MS (PPMS), where symptoms get worse over time. In an interview with pharmaphorum, Marius Scholtz, country medical lead for ...

This exploratory study assessed the safety and clinical benefit of masitinib in the treatment of primary progressive MS (PPMS) or relapse-free secondary progressive MS (rfSPMS). Methods ...

Susie Wyss used to inject herself daily with a medication for multiple sclerosis. “The injection hurt. It caused welts, bruises, and sometimes permanent lipoatrophy,” Wyss told more than 800 people ...

People with primary progressive MS (PPMS) experience a steady worsening ... involves symptom management and disease-modifying medications. People newly diagnosed with MS and those considered ...

The most common question is about what type of MS do I have. So we'll go online, and I'll see this relapsing, remitting, and primary progressive ... All of the medications we have right now ...

Elevated liver enzymes have also been seen with other BTK drugs, and Sanofi said that ... 3 trial called PERSEUS in patients with primary progressive MS (PPMS). Earlier this year, it abandoned ...

Commonly, progressive atrophy is the main feature of secondary progressive MS on brain MRI ... or immunomodulatory drug within 6 months of study entry. The primary outcome examined was the ...

The exact cause of MS is unknown, but it is thought US, NY, UNITED STATES, January 31, 2025 /EINPresswire / -- Multiple Sclerosis Ms Drugs market ... (RRMS), Primary Progressive Multiple Sclerosis ...